RESOURCES

Where research scientists come to find up to date resources on antibody discovery against challenging membrane protein targets.

Category: Uncategorized

Integral Molecular Partners with Philadelphia FIGHT Medical Clinic to Support Community Health

Integral Molecular announces a partnership with Philadelphia FIGHT to provide financial and in-kind donations, as well as volunteer efforts to support healthcare access and equity in Philadelphia. An anchor of the Philadelphia biotech community, Integral Molecular has been an active community citizen throughout its 20-year history. Philadelphia FIGHT operates federally qualified community health centers that provide culturally competent and comprehensive health services to all — regardless of income, insurance, or immigration status.

Integral Molecular’s mission is to develop and apply innovative technologies for difficult-to-treat diseases, and more recently to apply their technologies to combat COVID-19. The racial inequities in healthcare and beyond were brought into sharp relief during the pandemic. In 2020, Integral Molecular’s employees collectively decided to help actively address these inequities, including through the mission of Philadelphia FIGHT.

“Integral Molecular has deep ties to Philadelphia, and for the last 20 years we have been proud to give back through local educational programs including the University City Science Center’s BULB lab program, FirstHand STEM program, and the Wistar Institute’s Biomedical Technician Training Program,” said Sharon Willis PhD, co-founder of Integral Molecular. “We are excited to support FIGHT’s vital mission and continue our commitment to the community.”

Dr. Mario Cruz, MD, Philadelphia FIGHT’s Director of Pediatric and Adolescent Medicine has been working closely with Integral Molecular. When asked about working with the company he responded, “It’s rare to find a community partner that donates not just money, but also time. In addition to the funds, they donated 60 hours of their time and energy, physically helping to beautify our pediatric and adolescent practices — and they donated 300 books! It’s a genuine commitment to support our mission and it is very much appreciated. We are delighted to get to know this team, and the passion for healthcare that drives their research.”

Companies or individuals interested in supporting Philadelphia FIGHT should contact Michael A. Marsico, Chief of Staff, mmarsico@fight.org, 215-525-0784.

About Integral Molecular

Integral Molecular (integralmolecular.com) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

About Philadelphia FIGHT

Philadelphia FIGHT (fight.org) is a Federally Qualified Health Center (FQHC) providing high-quality medical care, including HIV and Hepatitis C primary care, pediatrics, family dentistry, gender-affirming care, behavioral health services, consumer education, clinical research, and advocacy for individuals and families from all walks of life and at every stage of life, REGARDLESS OF ABILITY TO PAY. 

RVP Users’ Group: Omicron RVPs and their role in safe neutralization assessment | February 15th, 11am ET

Join this users’ group to learn about our extensive catalog of SARS-CoV-2 Reporter Virus Particles (RVPs, pseudotyped viruses) including Omicron, and how they enable researchers to rapidly test neutralization titers of antibodies and vaccine sera in a safe BSL-2 environment.

Watch the webinar

We will discuss:

  • Integral Molecular’s extensive catalog of >65 SARS-CoV-2 Reporter Virus Particles (RVPs) and how they can help you safely assess virus neutralization
  • New offerings including Omicron RVPs (available now), and specialized reagents coming soon
  • Case studies of antibodies that bind Spike but permit infection, highlighting the importance of assaying neutralization



Integral Molecular Adds Transgenic Humanized Mice to Expand its MPS Antibody Discovery Platform Through a Partnership with Alloy Therapeutics

PHILADELPHIA — Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, has entered into an agreement to leverage Alloy Therapeutics’ transgenic humanized ATX-GxTM mice as an added strategy to rapidly isolate fully human monoclonal antibodies using Integral Molecular’s MPS Antibody Discovery platform. ATX-GxTM is a suite of immunologically robust transgenic mice that produce antibodies with fully human sequences. Lacking non-human sequences that can trigger severe immune side-effects, the resulting antibodies have high developability.

Integral Molecular’s MPS platform is optimized for discovering MAbs against structurally complex membrane proteins, a valuable group of therapeutic targets. With a 95% success rate in delivering antibodies targeting complex membrane proteins, MPS successes include antibodies recently licensed to Context Therapeutics (Nasdaq: CNTX) and AstraZeneca (LSE/STO/Nasdaq: AZN). Alloy’s ATX-GxTM mice complement Integral Molecular’s proprietary humanized chicken antibody technology (hCAT) now allowing partners to choose their preferred method to isolate fully humanized antibodies.

“We look forward to working with Integral Molecular as a Certified Service Provider to make our antibody discovery platform available to more drug discovery teams,” said Heather Schwoebel, Alloy Therapeutics’ Chief Operating Officer and Head of Business Development. “By harnessing Integral’s technologies, we have already seen exceptional immune responses to difficult targets, such as GPCRs, in the Alloy mice.”

Partners interested in antibody discovery should contact Integral Molecular.

About Integral Molecular

Integral Molecular (integralmolecular.com) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

About Alloy Therapeutics

Alloy Therapeutics (alloytx.com) is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, Alloy democratizes access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. Alloy’s lead offering, the ATX-Gx™ platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Alloy is headquartered in Boston, MA with labs in Cambridge, UK; Basel, CH; San Francisco, CA; and Athens, GA.

 

Integral Molecular Enables Rapid Resistance Testing of Vaccines and Drugs Against Emerging Coronavirus Variants

PHILADELPHIA — In response to the evolving COVID-19 pandemic, Integral Molecular has adapted its SARS-CoV-2 reporter virus particle (RVP) technology to reflect emerging virus variants, enabling safe laboratory testing for viral resistance to vaccines and drugs. The expanded RVP collection encompasses notable variants identified in the UK, South Africa, Japan, Brazil and other countries, as well as over 1,200 other mutants. 

“Since the onset of the pandemic, we have anticipated the emergence of viral variants and have been concerned about the potential development of resistant strains,” said Kyle Doolan, PhD, Senior Project Leader for molecular biology at Integral Molecular. “To stay ahead of the virus, we developed a rapidly adaptable platform to create RVP variants. Through continuous vigilance we can bring these updated tools to the scientific community on an almost weekly basis.”

SARS-CoV-2 RVPs contain the coronavirus spike protein, the primary target of the human immune response, and carry a non-infectious genome that produces an easily measured fluorescent or light emitting signal upon cellular infection. Integral Molecular has over a decade of experience producing large-scale batches of quality-controlled RVPs which are being used as critical reagents in vaccine clinical trials.

Integral Molecular’s scientific team will be discussing the use of SARS-CoV-2 RVP variants for resistance testing on February 10, 2021. Partners interested in using SARS-CoV-2 RVPs for their research or diagnostic assays should contact Integral Molecular.

About Integral Molecular

Integral Molecular (www.integralmolecular.com) is the industry leader in discovering and characterizing therapeutic antibodies against membrane proteins, an important group of drug targets found on the surfaces of cells and viruses. Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, auto-immune disorders and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue.

LinkedIn
Twitter
Email
Integral Molecular Awarded Grant from the Commonwealth of Pennsylvania to Advance COVID-19 Research

PHILADELPHIA – Integral Molecular has been awarded $521,723 from the Commonwealth of Pennsylvania to leverage its technologies in the global fight against COVID-19. Integral Molecular is at the forefront of the fight against COVID-19, with their technologies being used by over 100 laboratories worldwide to advance COVID-19 vaccine and therapeutic development. This grant will enable Integral Molecular and its partners to develop therapeutics and vaccines with broad specificity against SARS-CoV-2 variants.

“As a founding member and leader in the Philadelphia biotechnology community, Integral Molecular brings 20 years of virology experience and unique tools to the fight against COVID-19,” said Christopher Molineaux, President and CEO of Life Sciences PA. “We are proud that the science being done in Pennsylvania is having an impact on a global scale.”

The scientific team at Integral Molecular has mobilized four of its technology platforms against the virus. This includes using its MPS Antibody Discovery platform to generate broadly reactive antibodies against SARS-CoV-2 and other coronaviruses. SARS-CoV-2 Reporter Virus Particles (RVPs) have been adopted by vaccine companies to safely test for neutralizing immune responses in patients and vaccinees. Integral Molecular’s Membrane Protein Array (MPA) is being used to rapidly screen the specificity of SARS-CoV-2 antibodies to advance the most promising candidates, and Shotgun Mutagenesis Epitope Mapping is being used to optimize vaccine and antibody design, so that resulting therapeutics and vaccines recognize emerging SARS-CoV-2 variants.

“Our technologies enable us to predict and test virus mutations that can result in resistance to treatments or vaccines,” said Benjamin Doranz, PhD, President and CEO of Integral Molecular. “Containing this pandemic is our immediate goal, but the challenge ahead is to prevent its recurrence in the future.”

Integral Molecular is honored to receive grant funding through the COVID-19 Vaccines, Treatments and Therapies (CV-VTT) program, administered by Dennis Davin, Secretary of the Department of Community and Economic Development (DCED) of the Commonwealth of Pennsylvania.

Science Center to Honor Leaders of Innovation Community at Annual Nucleus Awards

Benjamin Doranz Nucleus Award
PHILADELPHIA–(August 20, 2020) – The University City Science Center will recognize three local leaders during its annual Nucleus Awards event on September 22, 2020, presented by CSL Behring. This year’s class of honorees includes Benjamin Doranz, President & CEO of Integral Molecular, Aurora Archer, Founder & CEO of Bellatrix Group and Co-Host of The Opt-In Podcast, and Sylvester Mobley, CEO of Coded by Kids. The awards will be presented to the recipients during a one-hour virtual event hosted by WHYY’s Tracey Matisak.

Each fall, Nucleus brings together the region’s leaders and groundbreakers in innovation, all while supporting Philadelphia’s future as a hub of innovation and discovery. Funds raised through Nucleus help sustain Science Center programs, which in 2019 alone supported the growth of 118 businesses; convened more than 39,000 attendees across 475 events; and engaged over 370 middle and high school students through its STEM education initiatives.

“This year’s honorees exemplify the very best of what our region’s entrepreneurial ecosystem has to offer in our shared pursuit of improving the lives of people around the world,” says Bill Mezzanotte, M.D., M.P.H., Executive Vice President, Head of R&D and Chief Medical Officer for CSL Behring – company sponsor of this year’s Nucleus Awards – and member of the University City Science Center Board of Directors.

“Congratulations to Ben, Aurora and Sylvester for your outstanding examples of the tangible impact that novel technologies can have on quality of life, economic development and societal welfare.”

BENJAMIN DORANZ
President and CEO of Integral Molecular
Commercialization Award
Sponsored by NewSpring Capital

Ben Doranz is President and CEO of Integral Molecular. Founded in 2001 at the Science Center and current uCity Square resident, Integral Molecular is a founding member of the Philadelphia biotech community with a history of excellence in antibody discovery for difficult to treat diseases and research in emerging viruses. In 2020 Integral Molecular rapidly pivoted its research and development programs in an effort to combat the COVID-19 pandemic. With support from the National Institute of Health and a team of talented scientists, Integral Molecular rapidly adapted many of its platform technologies to launch a suite of research solutions to accelerate the development of SARS-CoV-2 therapeutics. These include Reporter Virus Particles (RVPs) to test for the presence of neutralizing antibodies in vaccinees and technologies to assess the breadth of human immune responses against this virus.

Dr. Doranz co-founded Integral Molecular together with colleagues from the University of Pennsylvania using virus-based technologies. He has led all aspects of the company’s growth since its inception, bringing five different technologies from research to market. His efforts have cultivated a company that is profitable while being actively engaged with the local community. Dr. Doranz is an established life science entrepreneur previously responsible for helping create startups at the Center for Technology Transfer at the University of Pennsylvania. Dr. Doranz earned a Ph.D. in Cellular and Molecular Biology from the University of Pennsylvania, an M.B.A. from the Wharton School of Business at the University of Pennsylvania, and a B.A. from Cornell University.

For more information about Nucleus or to purchase tickets, visit www.ucscNucleus.org.

Integral Molecular Develops Test for Neutralizing Antibodies in COVID-19 Patients and Clinical Trials

PHILADELPHIA – Integral Molecular announces the launch of SARS-CoV-2 Reporter Virus Particles (RVPs) to test patients for the presence of neutralizing antibodies, determine the effectiveness of vaccines, and measure the efficacy of drugs to enable expedited testing of new vaccines and therapeutics. As part of its commitment to supporting COVID-19 research, Integral Molecular will provide scientists with access to samples of SARS-CoV-2 RVPs at no cost.

Traditional diagnostic blood tests can only detect the presence or absence of antibodies. In contrast, SARS-CoV-2 RVPs assess the ability of antibodies to neutralize (block) virus infection. This distinction is crucial since neutralizing antibodies are the ones that typically offer protection from disease. SARS-CoV-2 RVPs eliminate the need to use live virus for neutralization assays and are safe using standard (BSL-2) laboratory conditions, quantitative, and amenable to high-throughput screening.

“With 20 years of virology experience, Integral Molecular is the industry leader in providing RVPs for therapeutic antibody development and vaccine clinical trials,” said Benjamin Doranz, President and CEO of Integral Molecular. “Like our other reporter viruses, we expect that coronavirus RVPs will be used to determine if serum from vaccinees contain protective antibodies, if new therapeutic antibodies can kill the virus, and if convalescent COVID-19 patients have protective serum that can be used in therapy.”

SARS-CoV-2 RVPs contain the coronavirus spike protein, which is the primary target of the human immune response, and carry a non-infectious genome that produces an easily measured fluorescent or light emitting signal upon cellular infection. Integral Molecular has extensive experience producing large-scale batches of quality-controlled RVPs for dengue and Zika viruses (Mattia et al., 2011, and Whitbeck et al., 2020), which are being used as critical reagents in vaccine clinical trials.

Integral Molecular has already begun shipping SARS-CoV-2 RVPs to partners, and will be discussing the SARS-CoV-2 reporter viruses at a webinar on May 12. Partners interested in using SARS-CoV-2 RVPs for their research or diagnostic assays should contact Integral Molecular.

About Integral Molecular
Integral Molecular (www.integralmolecular.com) is the industry leader in discovering and characterizing therapeutic antibodies against membrane proteins, an important group of drug targets found on the surfaces of cells and viruses. Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 300 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, auto-immune disorders and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue.

Integral Molecular Receives NIAID Award to Combat COVID-19

PHILADELPHIA – The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular $1 million to enable the application of Integral Molecular’s technology platforms to aid in the discovery of vaccines and therapeutics to combat COVID-19.

Integral Molecular’s Shotgun Mutagenesis Epitope Mapping platform precisely identifies where antibodies bind to their target proteins, and will be used to design an improved vaccine and to identify the best therapeutic antibody candidates and combination cocktails.

SARS-CoV-2 Reporter Virus Particles are safe and non-replicating virus particles that display the coronavirus spike protein, the major viral protein targeted by the immune system. Reporter viruses provide developers an alternative to using live infectious virus, allowing antibodies, therapeutic drugs, and serum from vaccinated patients to be rapidly tested under safe laboratory conditions.

The company will use its Membrane Proteome Array platform of 6,000 human proteins to identify additional proteins that allow the virus to invade cells, helping to explain how the virus has been able to spread so quickly. The company’s Membrane Proteome Array platform has already been used to identify multiple receptors used by other viruses.

“We are pleased to support the scientific community around the world with our expertise and technologies in response to this pandemic,” said Benjamin Doranz, President and CEO of Integral Molecular. “We are fortunate to have financial support from NIAID to rapidly develop a suite of reagents and solutions that will make an impact on the speed of vaccine development and therapeutic testing.”

Integral Molecular has similarly responded to previous epidemics, including Zika, Ebola, and Chikungunya viruses. Since 2009, Integral has been awarded three consecutive contracts by NIAID to study viral immune responses, publishing over 50 virus-related publications including in high profile journals such as Cell and Nature.

This project has been funded by NIAID/NIH under Contract 75N93019C00073.

About Integral Molecular

Integral Molecular (www.integralmolecular.com) is the industry leader in discovering and characterizing therapeutic antibodies against membrane proteins, an important group of drug targets found on the surfaces of cells and viruses. Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 300 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, auto-immune disorders and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue.

Press Contact:
Integral Molecular Inc,
Soma Banik, PhD, Director of Communications
215-966-6061
info@integralmolecular.com
www.integralmolecular.com